Swiss National Bank lifted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 81,400 shares of the company’s stock after buying an additional 1,700 shares during the period. Swiss National Bank owned about 0.15% of Kymera Therapeutics worth $2,032,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the stock. American International Group Inc. grew its holdings in Kymera Therapeutics by 3.7% during the second quarter. American International Group Inc. now owns 17,698 shares of the company’s stock worth $348,000 after buying an additional 638 shares in the last quarter. TD Asset Management Inc grew its holdings in Kymera Therapeutics by 1.1% during the fourth quarter. TD Asset Management Inc now owns 79,515 shares of the company’s stock worth $1,985,000 after buying an additional 900 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in Kymera Therapeutics by 2.4% during the third quarter. Ensign Peak Advisors Inc now owns 47,547 shares of the company’s stock worth $1,035,000 after buying an additional 1,130 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Kymera Therapeutics by 32.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,985 shares of the company’s stock worth $124,000 after buying an additional 1,225 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in Kymera Therapeutics during the first quarter worth $53,000.
Analysts Set New Price Targets
Several brokerages recently issued reports on KYMR. Raymond James upgraded Kymera Therapeutics from a “market perform” rating to an “outperform” rating in a report on Thursday, May 4th. HC Wainwright restated a “buy” rating and issued a $85.00 price objective on shares of Kymera Therapeutics in a research note on Friday, February 24th. Finally, Credit Suisse Group upped their price objective on Kymera Therapeutics from $32.00 to $39.00 and gave the company a “neutral” rating in a research note on Friday, February 24th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $47.22.
Kymera Therapeutics Price Performance
Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last issued its quarterly earnings results on Thursday, May 4th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.01). The firm had revenue of $9.47 million for the quarter, compared to analysts’ expectations of $14.15 million. Kymera Therapeutics had a negative net margin of 340.80% and a negative return on equity of 34.15%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.71) EPS. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -2.66 EPS for the current fiscal year.
Insider Buying and Selling
In related news, CFO Bruce N. Jacobs sold 1,370 shares of the stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $31.00, for a total transaction of $42,470.00. Following the sale, the chief financial officer now owns 104,568 shares of the company’s stock, valued at approximately $3,241,608. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 17.01% of the stock is currently owned by insiders.
About Kymera Therapeutics
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
- Get a free copy of the StockNews.com research report on Kymera Therapeutics (KYMR)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating).
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.